炎症性肠病合并肝胆胰疾病的流行病学特征

李静; 王玉芳

doi:10.3969/j.issn.1001-5256.2020.07.005

炎症性肠病合并肝胆胰疾病的流行病学特征

DOI: 10.3969/j.issn.1001-5256.2020.07.005

李静,
王玉芳

华西临床医学院四川大学华西医院

详细信息

中图分类号: R575;R181.3;R574
计量
- 文章访问数: 1360
- HTML全文浏览量: 30
- PDF下载量: 156
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Epidemiological features of inflammatory bowel disease with hepatobiliary and pancreatic diseases

West China Medical School, West China Hospital of Sichuan University, Chengdu 610041, China

摘要

摘要:
肝胆胰疾病是炎症性肠病(IBD)的常见合并症,合并肝胆胰疾病可能影响IBD的诊断、治疗及预后,并对发现IBD病因具有一定的价值。阐述了IBD合并肝胆胰疾病的流行病学,以期能为认识IBD的发病机制和临床治疗方案制订提供新的启示。
- 炎症性肠病 /
- 肝疾病 /
- 胆道疾病 /
- 胰腺疾病 /
- 流行病学
Abstract:
Hepatobiliary and pancreatic diseases are common comorbidities of inflammatory bowel disease( IBD),and the presence of such diseases may affect the diagnosis,treatment,and prognosis of IBD and has certain value in identifying the cause of IBD. This article elaborates on the epidemiology of IBD with hepatobiliary and pancreatic diseases,so as to provide new insights for understanding the pathogenesis of IBD and formulating effective clinical treatment regimens.
- inflammatory bowel disease /
- liver diseases /
- biliary tract diseases /
- pancreatic diseases /
- epidemiology

HTML全文

参考文献(57)

[1]NG SC,SHI HY,HAMIDI N,et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:A systematic review of population-based studies[J].Lancet,2018,390(10114):2769-2778．

[2]HE Q,LI JD.Epidemiological progress of inflammatory bowel disease[J].J Pract Med,2019,35(18):2962-2966.(in Chinese)何琼，李建栋．炎症性肠病流行病学研究进展[J]．实用医学杂志，2019,35(18):2962-2966．

[3]CHAO CY,BATTAT R,AL KHOURY A,et al.Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease:Areview article[J].World J Gastroenterol,2016,22(34):7727-7734．

[4]FENG G,MI M,LI XP,et al.The economic burden and risk factors in inflammatory bowel disease with nonalcoholic fatty liver disease[J].J Clin Hepatol,2018,34(12):2702-2706.(in Chinese)冯巩，弥曼，李雪萍，等．炎症性肠病合并非酒精性脂肪性肝病的经济负担及危险因素[J]．临床肝胆病杂志，2018,34(12):2702-2706．

[5]SAROLI PALUMBO C,RESTELLINI S,CHAO CY,et al.Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases:A cohort study using transient elastography[J].Inflamm Bowel Dis,2019,25(1):124-133．

[6]PRINCIPI M,IANNONE A,LOSURDO G,et al.Nonalcoholic fatty liver disease in inflammatory bowel disease:Prevalence and risk factors[J].Inflamm Bowel Dis,2018,24(7):1589-1596．

[7]GLASSNER K,MALATY HM,ABRAHAM BP.Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2017,23(6):998-1003．

[8]ZOU ZY,SHEN B,FAN JG.Systematic review with meta-analysis:Epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2019,25(11):1764-1772．

[9]RESTELLINI S,CHAZOUILLRES O,FROSSARD JL.Hepatic manifestations of inflammatory bowel diseases[J].Liver Int,2017,37(4):475-489．

[10]SHAMBERG L,VAZIRI H.Hepatotoxicity of inflammatory bowel disease medications[J].J Clin Gastroenterol,2018,52(8):674-684．

[11]SILVA J,BRITO BS,SILVA I,et al.Frequency of hepatobiliary manifestations and concomitant liver disease in inflammatory bowel disease patients[J].Biomed Res Int,2019,2019:7604939．

[12]BJRNSSON ES,GU J,KLEINER DE,et al.Azathioprine and 6-mercaptopurine-induced liver injury:Clinical features and outcomes[J].J Clin Gastroenterol,2017,51(1):63-69．

[13]CONWAY R,LOW C,COUGHLAN RJ,et al.Risk of liver injury among methotrexate users:A meta-analysis of randomised controlled trials[J].Semin Arthritis Rheum,2015,45(2):156-162．

[14]SHELTON E,CHAUDREY K,SAUK J,et al.New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease[J].Aliment Pharmacol Ther,2015,41(10):972-979．

[15]ANTEZANA A,SIGAL S,HERBERT J,et al.Natalizumab-induced hepatic injury:A case report and review of literature[J].Mult Scler Relat Disord,2015,4(6):495-498．

[16]MAHFOUZ M,MARTIN P,CARRION AF.Hepatic complications of inflammatory bowel disease[J].Clin Liver Dis,2019,23(2):191-208．

[17]DEFILIPPIS EM,KUMAR S.Clinical presentation and outcomes of autoimmune hepatitis in inflammatory bowel disease[J].Dig Dis Sci,2015,60(10):2873-2880．

[18]CHEN D,LUO S,BEN Q,et al.Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China[J].Eur J Gastroenterol Hepatol,2017,29(5):509-515．

[19]Inflammatory Bowel Disease Group,Chinese Society of Gastroenterology,Chinese Medical Association.Evidence-based consensus on opportunistic infections in inflammatory bowel disease(republication)[J].Intest Res,2018,16(2):178-193．

[20]PERRILLO RP,GISH R,FALCK-YTTER YT.American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology,2015,148(1):221-244.e3．

[21]LORAS C,GISBERT JP,MNGUEZ M,et al.Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy[J].Gut,2010,59(10):1340-1346．

[22]HARBORD M,ANNESE V,VAVRICKA SR,et al.The first European evidencebased consensus on extra-intestinal manifestations in inflammatory bowel disease[J].J Crohn Colitis,2016,10(3):239-254．

[23]NAYMAGON L,TREMBLAY D,ZUBIZARRETA N,et al.The natural history,treatments,and outcomes of portal vein thrombosis in patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2020.[Online ahead of print]

[24]LIN JN,LIN CL,LIN MC,et al.Pyogenic liver abscess in patients with inflammatory bowel disease:A nationwide cohort study[J].Liver Int,2016,36(1):136-144．

[25]FOUSEKIS FS,KATSANOS KH,THEOPISTOS VI,et al.Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases:A referral center study[J].BMC Gastroenterol,2019,19(1):48．

[26]FAGAGNINI S,HEINRICH H,ROSSEL JB,et al.Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases[J].PLo S One,2017,12(10):e0185193．

[27]CHEN CH,LIN CL,KAO CH.Association between inflammatory bowel disease and cholelithiasis:A nationwide population-based cohort study[J].Int J Environ Res Public Health,2018,15(3):513．

[28]ZHANG FM,XU CF,SHAN GD,et al.Is gallstone disease associated with inflammatory bowel diseases?A meta-analysis[J].J Dig Dis,2015,16(11):634-641．

[29]LINDOR KD,KOWDLEY KV,HARRISON ME.ACG clinical guideline:Primary sclerosing cholangitis[J].Am J Gastroenterol,2015,110(5):646-660．

[30]TABIBIAN JH,ALI AH,LINDOR KD.Primary sclerosing cholangitis,part1:Epidemiology,etiopathogenesis,clinical features,and treatment[J].Gastroenterol Hepatol(N Y),2018,14(5):293-304．

[31]DYSON JK,BEUERS U,JONES D,et al.Primary sclerosing cholangitis[J].Lancet,2018,391(10139):2547-2559．

[32]LIU K,WANG R,KARIYAWASAM V,et al.Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort[J].Liver Int,2017,37(3):442-448．

[33]WEISMLLER TJ,TRIVEDI PJ,BERGQUIST A,et al.Patient age,sex,and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis[J].Gastroenterology,2017,152(8):1975-1984.e8．

[34]CHANG M,CHANG L,CHANG HM,et al.Intestinal and extraintestinal cancers associated with inflammatory bowel disease[J].Clin Colorectal Cancer,2018,17(1):e29-e37．

[35]LUNDER AK,HOV JR,BORTHNE A,et al.Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease[J].Gastroenterology,2016,151(4):660-669.e4．

[36]RAMOS LR,SACHAR DB,DIMAIO CJ,et al.Inflammatory bowel disease and pancreatitis:A review[J].J Crohn's Colitis,2016,10(1):95-104．

[37]ANTONINI F,PEZZILLI R,ANGELELLI L,et al.Pancreatic disorders in inflammatory bowel disease[J].World J Gastrointest Pathophysiol,2016,7(3):276-282．

[38]PEZZILLI R,PAGANO N.Benign exocrine pancreatic diseases in inflammatory bowel diseases[J].Dig Dis,2017,35(5):449-453．

[39]YADAV D,LOWENFELS AB.The epidemiology of pancreatitis and pancreatic cancer[J].Gastroenterology,2013,144(6):1252-1261．

[40]GARCIA GARCIA DE PAREDES A,RODRIGUEZ DE SANTIAGO E,RODRIGUEZ-ESCAJA C,et al.Idiopathic acute pancreatitis in patients with inflammatory bowel disease:A multicenter cohort study[J].Pancreatology,2020,20(3):331-337．

[41]KIM JW,HWANG SW,PARK SH,et al.Clinical course of ulcerative colitis patients who develop acute pancreatitis[J].World J Gastroenterol,2017,23(19):3505-3512．

[42]PEDERSEN JE,NGQUIST LH,JENSEN CB,et al.Risk of pancreatitis in patients with inflammatory bowel disease-a meta-analysis[J].Dan Med J,2020,67(3):A08190427．

[43]CHEN YT,SU JS,TSENG CW,et al.Inflammatory bowel disease on the risk of acute pancreatitis:A population-based cohort study[J].J Gastroenterol Hepatol,2016,31(4):782-787．

[44]SRINATH AI,GUPTA N,HUSAIN SZ.Probing the association of pancreatitis in inflammatory bowel disease[J].Inflamm Bowel Dis,2016,22(2):465-475．

[45]CHEN YL,HSU CW,CHENG CC,et al.Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis:A nationwide population-based cohort study[J].Curr Med Res Opin,2017,33(6):1077-1082．

[46]FOUSEKIS FS,THEOPISTOS VI,KATSANOS KH,et al.Pancreatic involvement in inflammatory bowel disease:A review[J].J Clin Med Res,2018,10(10):743-751．

[47]UEKI T,KAWAMOTO K,OTSUKA Y,et al.Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease[J].Pancreas,2015,44(3):434-440．

[48]MARTN-DE-CARPI J,MORICZI M,PUJOL-MUNCUNILL G,et al.Pancreatic involvement in pediatric inflammatory bowel disease[J].Front Pediatr,2017,5:218．

[49]ROQUE RAMOS L,DIMAIO CJ,SACHAR DB,et al.Autoimmune pancreatitis and inflammatory bowel disease:Case series and review of the literature[J].Dig Liver Dis,2016,48(8):893-898．

[50]KAWA S,OKAZAKI K,NOTOHARA K,et al.Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis[J].J Gastroenterol,2015,50(7):805-815．

[51]LORENZO D,MAIRE F,STEFANESCU C,et al.Features of autoimmune pancreatitis associated with inflammatory bowel diseases[J].Clin Gastroenterol Hepatol,2018,16(1):59-67．

[52]HART PA,LEVY MJ,SMYRK TC,et al.Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis(type 2 autoimmune pancreatitis):The mayo clinic experience[J].Gut,2016,65(10):1702-1709．

[53]PARK SH,KIM D,YE BD,et al.The characteristics of ulcerative colitis associated with autoimmune pancreatitis[J].J Clin Gastroenterol,2013,47(6):520-525．

[54]SHEN XG,ZOU DW,LI ZS,et al.Inflammatory bowel disease complicating with pancreatic abnormalities:A single center analysis[J].Chin J Pancreatol,2018,18(3):193-195.(in Chinese)沈祥国，邹多武，李兆申，等．炎症性肠病合并胰腺病变单中心分析[J]．中华胰腺病杂志，2018,18(3):193-195．

[55]MOSHER CA,BROWN GR,WEIDEMAN RA,et al.Incidence of colorectal cancer and extracolonic cancers in veteran patients with inflammatory bowel disease[J].Inflamm Bowel Dis,2018,24(3):617-623．

[56]PEDERSEN N,DURICOVA D,ELKJAER M,et al.Risk of extraintestinal cancer in inflammatory bowel disease:Meta-analysis of population-based cohort studies[J].Am J Gastroenterol,2010,105(7):1480-1487．

[57]JUNG YS,HAN M,PARK S,et al.Cancer risk in the early stages of inflammatory bowel disease in korean patients:A nationwide population-based study[J].J Crohns Colitis,2017,11(8):954-962.

施引文献

资源附件(0)

访问统计